The European Medicines Agency (EMA) is a European Union agency for the evaluation of medicinal products.

Evaluation by the Board of Trustees and secretariat in performing their evaluation, the Board and the secretariat carry out the following activities

Finally, the Executive Board should monitor the follow up to this evaluation.

The Administrator reported to the Executive Board at its 2004 annual session that the Evaluation Office had initiated an independent evaluation.

At its second regular session 2002, the Executive Board of UNDP UNFPA recommended that the UNDP Evaluation Office undertake a global evaluation of gender mainstreaming in UNDP.

The law on medicines,

World Medicines Situation. WHO, 2004.

In this context, the Evaluation Office has been requested to report on the findings and recommendations to the Executive Board.

Provision of medicines and essential vaccines.

UNICEF could not provide the Board with its evaluation of the cost effectiveness of translating the manual into other official languages.

This evaluation will also prepare the UNHCR Audit Service for the external audit envisaged by the United Nations Board of Auditors.

These structures may include committees or groups to which the board has assigned duties regarding the oversight of executive remuneration, audit matters, appointments to the board, and the evaluation of management performance.

If herbal medicines and supplements are removed from sale, they argue, patients will have no alternative but to use conventional pharmaceutical medicines.

With the exception of the evaluation of the PRRO category, which was presented to the Board in February 2004, and WFP's experience with real time evaluation of EMOPs, presented in May 2004, work is in progress.

Free medicines are only part of the solution.

And this is how it works Patent holders, inventors that develop new medicines patent those inventions, but make those patents available to the Medicines Patent Pool. The Medicines Patent Pool then license those out to whoever needs access to those patents.

The Board requested a revised gender action plan for 2006 2007 based on the recommendations of the independent evaluation report on gender in UNDP.

Two main problems limit the availability of medicines today.

In some cases, combinations of these medicines are prescribed.

Poor girls and women still could not afford medicines.

The Medicines and Healthcare Products Regulatory Agency was formed in 2003 with the merger of the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA).

In 2010, UNITAID established the Medicines Patent Pool for HIV.

Some services are paid by patients directly, like unsubsidized medicines.

In accordance with the WFP evaluation policy approved by the Executive Board in October 2003, the Office of Evaluation (OEDE) focused in 2004 on evaluating corporate programme and policy issues, large scale humanitarian assistance programmes and country development programmes at their mid point.

An independent external panel would conduct a peer review of the evaluation function, the results of which would be included in the progress report on the evaluation function in UNICEF, to be submitted to the Executive Board at the annual session of 2006.

In paragraph 225, the Board recommended that UNHCR conduct an evaluation of its tsunami operations in order to apply lessons learned for future operations concerning natural disasters.

The ad hoc group agreed that the board should disclose whether it has a performance evaluation process in place, either for the board as a whole or for individual members. Disclosure should be made of how the board has evaluated its performance and how the results of the appraisal are being used.

The summary of the evaluation is submitted to the Board with a view to presenting the final report and the management response for full discussion in January 2005.

Government finances health care research because improved medicines are a public good.

Medical uses Ivabradine was approved by the European Medicines Agency in 2005.

Millions living with HIV AIDS do not have access to lifesaving medicines.

The Board appreciated the efforts made by the secretariat, United Nations field presences and United Nations funds and programmes to undertake evaluation missions of both ongoing and new projects.

Evaluation

Evaluation

Evaluation

First, Africa s poor cannot afford insecticide treated bed nets and the correct medicines.

Novartis has agreed to make these medicines available at the cost of production.

Some health services are paid for directly, for example, medicines issued on prescription.

Second, donor governments have failed to promote simple ways to ensure the availability of medicines in villages across the continent. Rather than shipping medicines to each country on the basis of estimated needs, donor agencies have set up a complicated purchasing system that has led to years of delay in getting medicines to the villages.

Novartis has agreed to make these medicines available at the cost of production. But, despite Novartis s large production capacity, donor agencies have failed to order, buy, and ship the medicines in the required amounts.

Rather than shipping medicines to each country on the basis of estimated needs, donor agencies have set up a complicated purchasing system that has led to years of delay in getting medicines to the villages.

Strengthening evaluation

(c) Evaluation.

(c) Evaluation

C. Evaluation